178 related articles for article (PubMed ID: 11501776)
1. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations.
Imai M; Jobo T; Sato R; Kawaguchi M; Kuramoto H
Eur J Gynaecol Oncol; 2001; 22(3):217-20. PubMed ID: 11501776
[TBL] [Abstract][Full Text] [Related]
2. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.
Kaku T; Yoshikawa H; Tsuda H; Sakamoto A; Fukunaga M; Kuwabara Y; Hataeg M; Kodama S; Kuzuya K; Sato S; Nishimura T; Hiura M; Nakano H; Iwasaka T; Miyazaki K; Kamura T
Cancer Lett; 2001 Jun; 167(1):39-48. PubMed ID: 11323097
[TBL] [Abstract][Full Text] [Related]
3. Primary hormonal treatment for early endometrial carcinoma.
Sardi J; Anchezar Henry JP; Paniceres G; Gomez Rueda N; Vighi S
Eur J Gynaecol Oncol; 1998; 19(6):565-8. PubMed ID: 10215442
[TBL] [Abstract][Full Text] [Related]
4. Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate.
Mitsushita J; Toki T; Kato K; Fujii S; Konishi I
Gynecol Oncol; 2000 Oct; 79(1):129-32. PubMed ID: 11006045
[TBL] [Abstract][Full Text] [Related]
5. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
[TBL] [Abstract][Full Text] [Related]
6. Hormonal therapy for women with stage IA endometrial cancer of all grades.
Park JY; Kim DY; Kim TJ; Kim JW; Kim JH; Kim YM; Kim YT; Bae DS; Nam JH
Obstet Gynecol; 2013 Jul; 122(1):7-14. PubMed ID: 23743459
[TBL] [Abstract][Full Text] [Related]
7. Conservative treatment of adenocarcinoma of the endometrium in young patients. Is it appropriate?
Vinker S; Shani A; Open M; Fenig E; Dgani R
Eur J Obstet Gynecol Reprod Biol; 1999 Mar; 83(1):63-5. PubMed ID: 10221612
[TBL] [Abstract][Full Text] [Related]
8. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.
Park JY; Lee SH; Seong SJ; Kim DY; Kim TJ; Kim JW; Kim JH; Kim YM; Kim YT; Bae DS; Nam JH
Gynecol Oncol; 2013 Apr; 129(1):7-11. PubMed ID: 23283299
[TBL] [Abstract][Full Text] [Related]
9. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Zaino RJ; Brady WE; Todd W; Leslie K; Fischer EG; Horowitz NS; Mannel RS; Walker JL; Ivanovic M; Duska LR
Int J Gynecol Pathol; 2014 Nov; 33(6):543-53. PubMed ID: 25272292
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of conservative therapy for young women with early endometrial adenocarcinoma.
Mao Y; Wan X; Chen Y; Lv W; Xie X
Fertil Steril; 2010 Jan; 93(1):283-5. PubMed ID: 19962142
[TBL] [Abstract][Full Text] [Related]
11. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
Hahn HS; Yoon SG; Hong JS; Hong SR; Park SJ; Lim JY; Kwon YS; Lee IH; Lim KT; Lee KH; Shim JU; Mok JE; Kim TJ
Int J Gynecol Cancer; 2009 Aug; 19(6):1068-73. PubMed ID: 19820370
[TBL] [Abstract][Full Text] [Related]
12. Treatment for complex atypical hyperplasia of the endometrium.
Jobo T; Kawaguchi M; Imai M; Kuramoto H
Eur J Gynaecol Oncol; 2001; 22(5):365-8. PubMed ID: 11766742
[TBL] [Abstract][Full Text] [Related]
13. Sparing fertility in young patients with endometrial cancer.
Chiva L; Lapuente F; González-Cortijo L; Carballo N; García JF; Rojo A; Gonzalez-Martín A
Gynecol Oncol; 2008 Nov; 111(2 Suppl):S101-4. PubMed ID: 18804267
[TBL] [Abstract][Full Text] [Related]
14. Unsuspected uterine carcinosarcoma (heterologous) diagnosed following conservative therapies with medroxyprogesterone acetate for presumed early-stage endometrial carcinoma.
Fujiwara H; Shibahara H; Usui R; Takamizawa S; Kosuge S; Ohwada M; Suzuki M; Sato I
Am J Reprod Immunol; 2002 Mar; 47(3):129-31. PubMed ID: 12069197
[No Abstract] [Full Text] [Related]
15. Long-term outcomes of fertility-sparing treatment of atypical polypoid adenomyoma with medroxyprogesterone acetate.
Nomura H; Sugiyama Y; Tanigawa T; Matoda M; Kanao H; Kondo E; Takeshima N
Arch Gynecol Obstet; 2016 Jan; 293(1):177-181. PubMed ID: 26209972
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger.
Ota T; Yoshida M; Kimura M; Kinoshita K
Int J Gynecol Cancer; 2005; 15(4):657-62. PubMed ID: 16014120
[TBL] [Abstract][Full Text] [Related]
17. The nuclear channel system in endometrial adenocarcinoma exposed to medroxyprogesterone acetate.
Horbelt DV; Delmore JE; Parmley TH; Roberts DK; Walker N
Hum Pathol; 1996 Jan; 27(1):9-14. PubMed ID: 8543319
[TBL] [Abstract][Full Text] [Related]
18. While women await surgery for type I endometrial cancer, depot medroxyprogesterone acetate reduces tumor glandular cellularity.
Fiascone S; Danilack VA; Kao MJ; Cohen M; Singh K; Kalife E; Luis C; Lokich E; DiSilvestro P; Robison K
Am J Obstet Gynecol; 2018 Oct; 219(4):381.e1-381.e10. PubMed ID: 30063901
[TBL] [Abstract][Full Text] [Related]
19. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
